Chronic pulmonary inflammation due to airborne pollutants leading to fibrosis with progressive loss of lung function is a major therapeutic challenge. Multiple mechanisms are involved, including airway cell death activating myeloid, innate and adaptive lymphoid cells with the release of inflammatory and pro-fibrotic mediators, fibroblast activation and proliferation with excessive collagen production.
Resolution of fibrotic pulmonary diseases is the focus of the present conference. Novel approaches using patient samples and experimental models, as well as the role of altered microbiota and metabolites, will be debated.
The commonly used experimental bleomycin-induced fibrosis model for IPF may provide insights into fibrosis resolution, unlike clinical IPF. Contributions on the polarization of myeloid cells, inhibition of fibroblasts, removal of fibrotic tissue or regeneration of alveolar epithelial cells by inhibitors and cell therapy are attractive. Therapies targeting specific molecular pathways enhancing fibrosis resolution is a major challenge for investigation.
This international conference is organised in the framework of the BIOPHARMACEUTICALS ARD CVL Programme.
Convenors
Prof. Remo C. Russo, LE STUDIUM Visiting researcher / ARD CVL biopharmaceuticals
FROM Federal University of Minas Gerais - BR
IN RESIDENCE AT Immuno - Neuro Modulation (INEM) / CNRS, University of Orléans - FR
Dr Valérie Quesniaux , Dr Bernhard Ryffel et Dr Isabelle Couillin
Immuno - Neuro Modulation (INEM) / CNRS, University of Orléans - FR
